BeiGene Says Israeli Ministry Of Health Approved TEVIMBRA (Tislelizumab) As Monotherapy For Treatment Of Adult Patients With Unresectable Or Metastatic OESCC After Prior Systemic Chemotherapy
BeiGene Says Israeli Ministry Of Health Approved TEVIMBRA (Tislelizumab) As Monotherapy For Treatment Of Adult Patients With Unresectable Or Metastatic OESCC After Prior Systemic Chemotherapy
百济神州表示,以TEVIMBRA(Tislelizumab)作为单药治疗成年患者复发性或转移性食管鳞状细胞癌经过先前系统化疗获得以色列卫生部批准
BeiGene Says Israeli Ministry Of Health Approved TEVIMBRA (Tislelizumab) As Monotherapy For Treatment Of Adult Patients With Unresectable Or Metastatic OESCC After Prior Systemic Chemotherapy
百济神州表示,以色列卫生部已批准TEVIMBRA(Tislelizumab)作为单药治疗不可切除或转移性食道鳞状细胞癌成人患者的先前全身化疗后的治疗